Pharma BD Deal Intelligence
Pfizer's ~$1.6B buy of AstraZeneca's ex-US anti-infectives portfolio (Zavicefta, Merrem/Meronem, Zinforo, plus pipeline asset ATM-AVI) never became core: mature brands declined, standalone revenue was never disclosed, and by late 2024 Pfizer was exploring a sale of the entire Hospital business unit under activist pressure.
A sub-scale antibiotics bolt-on that never became core — nearly a decade later Pfizer is trying to sell the whole business unit it sits in.
Full analysis, sources & comparables →John Young, Group President, Pfizer Essential Health: 'As we continue to reshape our Essential Health portfolio, we are focusing on areas that further address…
Analysts viewed the deal as a bargain price for a marketed and late-stage antibiotic portfolio, reflecting the broader industry retreat from anti-infectives…
Pfizer closed the AstraZeneca anti-infectives acquisition, adding Zavicefta and a Phase 3 ATM-AVI to one of the broadest hospital antibacterial portfolios in…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AstraZeneca sold its small molecule antibiotics business to Pfizer for up to $1.575B: $550M upfront cash, $175M deferred (paid January 2019), up to $250M in milestone payments, plus up to $600M in sales-related payments and tiered royalties on Zavicefta and ATM-AVI. Portfolio: marketed Zavicefta, Merrem, Zinforo plus clinical-stage ATM-AVI and CXL. Completed December 2016.
A sub-scale antibiotics bolt-on that never became core — nearly a decade later Pfizer is trying to sell the whole business unit it sits in.
Assessment window: 5yr post-close.
13K US cases/yr
Multidrug-resistant Gram-negative pathogens, particularly carbapenem-resistant Enterobacterales (CRE) and Pseudomonas aeruginosa, are CDC-classified urgent and serious public health threats causing ~12,700 US infections and >1,100 deaths annually. Bloodstream-infection mortality reaches 40-60%, making last-line agents like ceftazidime-avibactam essential to ICU and oncology supportive care.
Pfizer's August 2016 acquisition of AstraZeneca's small-molecule antibiotics business — $550M upfront, $175M deferred (paid Jan 2019), up to $250M milestones, plus up to $600M sales-based payments and tiered royalties — anchored Pfizer's leadership in MDR Gram-negative infection. The crown-jewel asset is Zavicefta (ceftazidime-avibactam), marketed in the US by Allergan/AbbVie as Avycaz under a separate Forest Labs licensing arrangement and in EU/RoW by Pfizer, used for complicated UTI, complicated intra-abdominal infection, and HAP/VAP. Zavicefta competes with Merck's Recarbrio (imipenem-cilastatin-relebactam), Shionogi's Fetroja (cefiderocol), Melinta's Vabomere (meropenem-vaborbactam), and Spero/Pfizer's tebipenem. Beyond Zavicefta, the deal included Merrem/Meronem (meropenem, generic since 2010), Zinforo (ceftaroline) for CABP/cSSSI, the clinical-stage ATM-AVI (aztreonam-avibactam, FDA-approved as Emblaveo April 2025 for MBL-producing Enterobacterales), and CXL (a CXCR antagonist program). The transaction was a strategic bet that Pfizer's hospital-channel scale could monetize antibiotics that AstraZeneca had de-prioritized as part of its oncology pivot — partially validated by Emblaveo's 2025 approval but constrained by the chronic difficulty of antibiotic commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Pfizer Inc. (this deal) | 2016 | $1.6B | 36 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2016 deals · AstraZeneca PLC deals · Infectious Disease deals